Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand.
The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Abstract
Bone remodelling and bone loss are controlled by a balance between the tumour necrosis factor family molecule osteoprotegerin ligand (OPGL) and its decoy receptor osteoprotegerin (OPG). In addition, OPGL regulates lymph node organogenesis, lymphocyte development and interactions between T cells and dendritic cells in the immune system. The OPGL receptor, RANK, is expressed on chondrocytes, osteoclast precursors and mature osteoclasts. OPGL expression in T cells is induced by antigen receptor engagement, which suggests that activated T cells may influence bone metabolism through OPGL and RANK. Here we report that activated T cells can directly trigger osteoclastogenesis through OPGL. Systemic activation of T cells in vivo leads to an OPGL-mediated increase in osteoclastogenesis and bone loss. In a T-cell-dependent model of rat adjuvant arthritis characterized by severe joint inflammation, bone and cartilage destruction and crippling, blocking of OPGL through osteoprotegerin treatment at the onset of disease prevents bone and cartilage destruction but not inflammation. These results show that both systemic and local T-cell activation can lead to OPGL production and subsequent bone loss, and they provide a novel paradigm for T cells as regulators of bone physiology.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“RANKL is produced by numerous cell types including cells of the osteoblast lineage (46,47) and activated T cells (42,48,49).”
From Receptor Activator of Nuclear Factor κB Ligand and Osteoprotegerin Regulation of Bone Remodeling in Health and Disease (2008) · cites this paper as [49]
In the citing paper
“T Cells express both soluble and membrane-bound forms of RANKL (49,50), and both forms are implicated in focal bone erosions associated with inflammatory arthritis (26,49).”
From Receptor Activator of Nuclear Factor κB Ligand and Osteoprotegerin Regulation of Bone Remodeling in Health and Disease (2008) · cites this paper as [49]
In the citing paper
“Within the developed immune system, RANKL is expressed by T cells (42), RANK is expressed by dendritic cells (49), and OPG is expressed by B lymphocytes and dendritic cells (4,70).”
From Receptor Activator of Nuclear Factor κB Ligand and Osteoprotegerin Regulation of Bone Remodeling in Health and Disease (2008) · cites this paper as [49]
In the citing paper
“However, RANK and RANKL knockout mice had normal Peyer's patches and intact splenic architecture (49,62), indicating that the development of lymph nodes and secondary lymphoid organs can be differentially regulated.”
From Receptor Activator of Nuclear Factor κB Ligand and Osteoprotegerin Regulation of Bone Remodeling in Health and Disease (2008) · cites this paper as [49]
In the citing paper
“RANKL inhibition via recombinant OPG treatment also results in marked suppression of bone erosions and osteoclasts in several rodent models, including adjuvant arthritis (26,49,177,232,233), collagen-induced arthritis (26,181,233), and TNF-mediated arthritis (136, 234).”
From Receptor Activator of Nuclear Factor κB Ligand and Osteoprotegerin Regulation of Bone Remodeling in Health and Disease (2008) · cites this paper as [49]
3 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation.
Lacey, D. L., Timms, E., Tan, H.-L., Kelley, M. J., Dunstan, C. R., Burgess, T., Elliott, R., Colombero, A., Elliott, G., Scully, S., et al. (1998) · Cell · doi:10.1016/s0092-8674(00)81569-x · Cited by 5,439
Self-citationOsteoprotegerin: a novel secreted protein involved in the regulation of bone density.
Simonet, W. S., Lacey, D. L., Dunstan, C. R., Kelley, M., Chang, M.-S., Lüthy, R., Nguyen, H. Q., Wooden, S., Bennett, L., Boone, T., et al. (1997) · Cell · doi:10.1016/s0092-8674(00)80209-3 · Cited by 5,130
Self-citationOPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph node organogenesis.
Kong, Y.-Y., Yoshida, H., Sarosi, I., Tan, H.-L., Timms, E., Capparelli, C., Morony, S., Oliveira-dos-Santos, A. J., Van, G., Itie, A., et al. (1999) · Nature · doi:10.1038/16852 · Cited by 3,351 · cited 1×
“We show that: (1) p66 is serine phosphorylated upon treatment with hydrogen peroxide (H2O2) or irradiation with ultraviolet light; (2) ablation of p66 enhances cellular resistance to apoptosis induced by H2O2 or ultraviolet light; (3) a serinephosphorylation defective mutant of p66 cannot restore the normal stress res…”
BackgroundSelf-citationRAG-1-deficient mice have no mature B and T lymphocytes
Mombaerts, P., Iacomini, J., Johnson, R. S., Herrup, K., Tonegawa, S., & Papaioannou, V. E. (1992) · Cell · doi:10.1016/0092-8674(92)90030-g · Cited by 2,931
Lymphoproliferative Disorders with Early Lethality in Mice Deficient in Ctla-4
Waterhouse, P., Penninger, J. M., Timms, E., Wakeham, A., Shahinian, A., Lee, K. P., Thompson, C. B., Griesser, H., & Mak, T. W. (1995) · Science · doi:10.1126/science.270.5238.985 · Cited by 2,766
Self-citationROLE OF CYTOKINES IN RHEUMATOID ARTHRITIS
Feldmann, M., Brennan, F. M., & Maini, R. N. (1996) · Annual Review of Immunology · doi:10.1146/annurev.immunol.14.1.397 · Cited by 2,514
A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function.
Anderson, D. M., Maraskovsky, E., Billingsley, W. L., Dougall, W. C., Tometsko, M. E., Roux, E. R., Teepe, M. C., DuBose, R. F., Cosman, D., & Galibert, L. (1997) · Nature · doi:10.1038/36593 · Cited by 2,290
Kotake, S., Udagawa, N., Takahashi, N., Matsuzaki, K., Itoh, K., Ishiyama, S., Saito, S., Inoue, K., Kamatani, N., Gillespie, M. T., et al. (1999) · Journal of Clinical Investigation · doi:10.1172/jci5703 · Cited by 1,696
Hsu, H., Lacey, D. L., Dunstan, C. R., Solovyev, I., Colombero, A., Timms, E., Tan, H.-L., Elliott, G., Kelley, M. J., Sarosi, I., et al. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.7.3540 · Cited by 1,636
Self-citationWong, B. R., Rho, J., Arron, J., Robinson, E., Orlinick, J., Chao, M., Kalachikov, S., Cayani, E., Bartlett, F. S., Frankel, W. N., et al. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.40.25190 · Cited by 1,042
Cited by
Osteoclast differentiation and activation
Boyle, W. J., Simonet, W. S., & Lacey, D. L. (2003) · Nature · doi:10.1038/nature01658 · Cited by 6,670
“Activation of T cells in vitro and in vivo leads to increased osteoclastogenesis and bone resorption, suggesting that acute and chronic inflammatory states, and certain leukaemias, contribute to pathologic bone los”
Self-citationBone Resorption by Osteoclasts
Teitelbaum, S. L. (2000) · Science · doi:10.1126/science.289.5484.1504 · Cited by 3,962
The gut microbiota--masters of host development and physiology
Sommer, F., & Bäckhed, F. (2013) · Nature Reviews Microbiology · doi:10.1038/nrmicro2974 · Cited by 3,681
The TNF and TNF Receptor Superfamilies
Locksley, R. M., Killeen, N., & Lenardo, M. J. (2001) · Cell · doi:10.1016/s0092-8674(01)00237-9 · Cited by 3,650
Missing Pieces in the NF-κB Puzzle
Ghosh, S., & Karin, M. (2002) · Cell · doi:10.1016/s0092-8674(02)00703-1 · Cited by 3,638
Evolving concepts of rheumatoid arthritis
Firestein, G. S. (2003) · Nature · doi:10.1038/nature01661 · Cited by 3,605
“For instance, T-cell activation leads to a RANKL-mediated increase in osteoclasts and bone loss in rat adjuvant arthriti”
BackgroundRoodman, G. D. (2004) · New England Journal of Medicine · doi:10.1056/nejmra030831 · Cited by 2,755
Osteoporosis: now and the future
Rachner, T. D., Khosla, S., & Hofbauer, L. C. (2011) · The Lancet · doi:10.1016/s0140-6736(10)62349-5 · Cited by 2,696
Cytokines in the pathogenesis of rheumatoid arthritis
McInnes, I. B., & Schett, G. (2007) · Nature Reviews Immunology · doi:10.1038/nri2094 · Cited by 2,529
Cytokine Pathways and Joint Inflammation in Rheumatoid Arthritis
Choy, E. H. S., & Panayi, G. S. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103223441207 · Cited by 2,249
Osteoimmunology: shared mechanisms and crosstalk between the immune and bone systems
Takayanagi, H. (2007) · Nature Reviews Immunology · doi:10.1038/nri2062 · Cited by 1,878
“RANKL is not only expressed by the bone-forming osteoblasts that support osteoclastogenesis in bone tissue, but also by activated T cells, indicating that osteoclastic bone resorption is influenced by the immune syste”
BackgroundTherapeutic Approaches to Bone Diseases
Rodan, G. A., & Martin, T. J. (2000) · Science · doi:10.1126/science.289.5484.1508 · Cited by 1,767
Sato, K., Suematsu, A., Okamoto, K., Yamaguchi, A., Morishita, Y., Kadono, Y., Tanaka, S., Kodama, T., Akira, S., Iwakura, Y., et al. (2006) · The Journal of Experimental Medicine · doi:10.1084/jem.20061775 · Cited by 1,554
Minireview: The OPG/RANKL/RANK System
Khosla, S. (2001) · Endocrinology · doi:10.1210/endo.142.12.8536 · Cited by 1,515
“Finally, activated T cells (as in rheumatoid arthritis) have increased levels of RANKL expression (52) and RANKL, in the presence of M-CSF, can induce synovial macrophages to differentiate into osteoclastic bone-resorbing cells (53), thus potentially leading to the periarticular bone loss commonly seen in various form…”
Inflammatory and immune pathways in the pathogenesis of periodontal disease
Cekici, A., Kantarci, A., Hasturk, H., & Van Dyke, T. E. (2014) · Periodontology 2000 · doi:10.1111/prd.12002 · Cited by 1,415
T-Cell mediated regulation of osteoclastogenesis by signalling cross-talk between RANKL and IFN-γ.
Takayanagi, H., Ogasawara, K., Hida, S., Chiba, T., Murata, S., Sato, K., Takaoka, A., Yokochi, T., Oda, H., Tanaka, K., et al. (2000) · Nature · doi:10.1038/35046102 · Cited by 1,358
Matrix-embedded cells control osteoclast formation
Xiong, J., Onal, M., Jilka, R. L., Weinstein, R. S., Manolagas, S. C., & O'Brien, C. A. (2011) · Nature Medicine · doi:10.1038/nm.2448 · Cited by 1,304
Dickkopf-1 is a master regulator of joint remodeling
Diarra, D., Stolina, M., Polzer, K., Zwerina, J., Ominsky, M. S., Dwyer, D., Korb, A., Smolen, J., Hoffmann, M., Scheinecker, C., et al. (2007) · Nature Medicine · doi:10.1038/nm1538 · Cited by 1,298
Self-citationLam, J., Takeshita, S., Barker, J. E., Kanagawa, O., Ross, F. P., & Teitelbaum, S. L. (2000) · Journal of Clinical Investigation · doi:10.1172/jci11176 · Cited by 1,440
Anti-TNFα Therapy of Rheumatoid Arthritis: What Have We Learned?
Feldmann, M., & Maini, R. N. (2001) · Annual Review of Immunology · doi:10.1146/annurev.immunol.19.1.163 · Cited by 1,257
RANKL–RANK signaling in osteoclastogenesis and bone disease
Wada, T., Nakashima, T., Hiroshi, N., & Penninger, J. M. (2006) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2005.11.007 · Cited by 1,212
Self-citationTilg, H., Moschen, A. R., & Roden, M. (2017) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2016.147 · Cited by 1,002
New therapies for treatment of rheumatoid arthritis
Smolen, J. S., Aletaha, D., Koeller, M., Weisman, M. H., & Emery, P. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60784-3 · Cited by 995
Clinical Implications of the Osteoprotegerin/RANKL/RANK System for Bone and Vascular Diseases
Hofbauer, L. C. (2004) · JAMA · doi:10.1001/jama.292.4.490 · Cited by 988
Estrogen deficiency and bone loss: an inflammatory tale
Weitzmann, M. N. (2006) · Journal of Clinical Investigation · doi:10.1172/jci28550 · Cited by 990
Bone erosion in rheumatoid arthritis: mechanisms, diagnosis and treatment
Schett, G., & Gravallese, E. (2012) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2012.153 · Cited by 947
Therapeutic strategies for rheumatoid arthritis
Smolen, J. S., & Steiner, G. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1109 · Cited by 911
Changes in Proinflammatory Cytokine Activity after Menopause
Pfeilschifter, J., Köditz, R., Pfohl, M., & Schatz, H. (2002) · Endocrine Reviews · doi:10.1210/edrv.23.1.0456 · Cited by 914
The aging of the immune system
Weiskopf, D., Weinberger, B., & Grubeck-Loebenstein, B. (2009) · Transplant International · doi:10.1111/j.1432-2277.2009.00927.x · Cited by 908
Inflammatory bone loss: pathogenesis and therapeutic intervention
Redlich, K., & Smolen, J. S. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3669 · Cited by 830
Arron, J. R., & Choi, Y. (2000) · Nature · doi:10.1038/35046196 · Cited by 827
Kearns, A. E., Khosla, S., & Kostenuik, P. J. (2008) · Endocrine Reviews · doi:10.1210/er.2007-0014 · Cited by 824
The gut microbiota regulates bone mass in mice
Sjögren, K., Engdahl, C., Henning, P., Lerner, U. H., Tremaroli, V., Lagerquist, M. K., Bäckhed, F., & Ohlsson, C. (2012) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.1588 · Cited by 822
RANK-L and RANK: T Cells, Bone Loss, and Mammalian Evolution
Theill, L. E., Boyle, W. J., & Penninger, J. M. (2002) · Annual Review of Immunology · doi:10.1146/annurev.immunol.20.100301.064753 · Cited by 819
Self-citationTRANCE/RANKL knockout mice are protected from bone erosion in a serum transfer model of arthritis.
Pettit, A. R., Ji, H., von Stechow, D., Müller, R., Goldring, S. R., Choi, Y., Benoist, C., & Gravallese, E. M. (2001) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)63016-7 · Cited by 807
“Treatment with OPG also prevented osteoclast accumulation, whereas destruction of bone in untreated arthritic animals was accompanied by the accumulation of large numbers of TRAP osteoclast-like cells.(30) OPG treatment in an animal model of arthritis that is dependent on T-cell activation, however, has the potential…”
BackgroundResultInfluentialOsteoimmunology: evolving concepts in bone–immune interactions in health and disease
Tsukasaki, M., & Takayanagi, H. (2019) · Nature Reviews Immunology · doi:10.1038/s41577-019-0178-8 · Cited by 771
Bekker, P. J., Holloway, D. L., Rasmussen, A. S., Murphy, R., Martin, S. W., Leese, P. T., Holmes, G. B., Dunstan, C. R., & DePaoli, A. M. (2004) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.040305 · Cited by 771
Fata, J. E., Kong, Y.-Y., Li, J., Sasaki, T., Irie-Sasaki, J., Moorehead, R. A., Elliott, R., Scully, S., Voura, E. B., Lacey, D. L., et al. (2000) · Cell · doi:10.1016/s0092-8674(00)00103-3 · Cited by 756
Self-citationOsteoclasts: What Do They Do and How Do They Do It?
Teitelbaum, S. L. (2007) · The American Journal of Pathology · doi:10.2353/ajpath.2007.060834 · Cited by 730
“Although RANKL, in physiological circumstances, is principally expressed by mesenchymal cells of osteoblast lineage, the osteoclastogenic cytokine is produced in abundance, by T lymphocytes in states of skeletal inflammation such as rheumatoid arthritis.(11) In this circumstance, RANKL may be cleaved from the cell mem…”
OSTEOIMMUNOLOGY: Interplay Between the Immune System and Bone Metabolism
Walsh, M. C., Kim, N., Kadono, Y., Rho, J., Lee, S. Y., Lorenzo, J., & Choi, Y. (2006) · Annual Review of Immunology · doi:10.1146/annurev.immunol.24.021605.090646 · Cited by 724
Denosumab and bisphosphonates: Different mechanisms of action and effects
Baron, R., Ferrari, S., & Russell, R. G. G. (2011) · Bone · doi:10.1016/j.bone.2010.11.020 · Cited by 715
“However, when RANKL is produced by activated T cells during inflammatory processes such as colitis and rheumatoid arthritis (RA) in the absence of other immune molecule deficits, antagonizing RANK/RANKL signaling has no effect on proliferation or activation of inflammatory cells [93–97].”
BackgroundLubberts, E., Koenders, M. I., Oppers‐Walgreen, B., van den Bersselaar, L., Coenen‐de Roo, C. J. J., Joosten, L. A. B., & van den Berg, W. B. (2004) · Arthritis & Rheumatism · doi:10.1002/art.20001 · Cited by 709
Estrogen deficiency induces bone loss by enhancing T-cell production of TNF-α
Cenci, S., Weitzmann, M. N., Roggia, C., Namba, N., Novack, D., Woodring, J., & Pacifici, R. (2000) · Journal of Clinical Investigation · doi:10.1172/jci11066 · Cited by 705
“When taken together, the available data indicate that while M-CSF and RANKL are essential for physiologic osteoclast renewal (6) and RANKL is responsible for the bone loss associated with inflammation (7), TNF-α plays a key causal role in the bone involution characteristic of estrogen deficiency.”
BackgroundResultRole of RANK ligand in mediating increased bone resorption in early postmenopausal women
Eghbali-Fatourechi, G., Khosla, S., Sanyal, A., Boyle, W. J., Lacey, D. L., & Riggs, B. L. (2003) · Journal of Clinical Investigation · doi:10.1172/jci17215 · Cited by 825
“In an experimental mouse model of inflammatory arthritis, activated T lymphocytes expressing RANKL were shown to regulate the associated periarticular bone loss and joint destruction (46).”
BackgroundSelf-citationCurrent Understanding of RANK Signaling in Osteoclast Differentiation and Maturation
Park, J. H., Lee, N. K., & Lee, S. Y. (2017) · Molecules and Cells · doi:10.14348/molcells.2017.0225 · Cited by 645
“Mice with genetic deletions of Tnfsf11 or Tnfrsf11a exhibit severe osteopetrosis accompanied by defective tooth eruption owing to the complete death of their osteoclasts (Dougall et al., 1999; Kong et al., 1999; Li et al., 2000).”
BackgroundThe role of macrophages in osteolysis of total joint replacement
Ingham, E., & Fisher, J. (2005) · Biomaterials · doi:10.1016/j.biomaterials.2004.04.035 · Cited by 667
Theoleyre, S., Wittrant, Y., Tat, S. K., Fortun, Y., Redini, F., & Heymann, D. (2004) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2004.06.004 · Cited by 663
“Thus in rheumatoid arthritis, overexpression [36] of RANKL can induce synovial macrophages to differentiate into active osteoclasts leading to periarticular bone loss [145].”
BackgroundInfluentialRitchlin, C. T., Haas-Smith, S. A., Li, P., Hicks, D. G., & Schwarz, E. M. (2003) · Journal of Clinical Investigation · doi:10.1172/jci16069 · Cited by 616
The cell biology of bone metabolism
Datta, H. K., Ng, W. F., Walker, J. A., Tuck, S. P., & Varanasi, S. S. (2008) · Journal of Clinical Pathology · doi:10.1136/jcp.2007.048868 · Cited by 614
Role of receptor activator of nuclear factor-κB ligand and osteoprotegerin in bone cell biology
Hofbauer, L. C., & Heufelder, A. E. (2001) · Journal of Molecular Medicine · doi:10.1007/s001090100226 · Cited by 586
Cohen, S. B., Dore, R. K., Lane, N. E., Ory, P. A., Peterfy, C. G., Sharp, J. T., van der Heijde, D., Zhou, L., Tsuji, W., Newmark, R., et al. (2008) · Arthritis & Rheumatism · doi:10.1002/art.23417 · Cited by 576
Kawai, T., Matsuyama, T., Hosokawa, Y., Makihira, S., Seki, M., Karimbux, N. Y., Goncalves, R. B., Valverde, P., Dibart, S., Li, Y.-P., et al. (2006) · The American Journal of Pathology · doi:10.2353/ajpath.2006.060180 · Cited by 565
Osteoimmunology: Interactions of the Bone and Immune System
Lorenzo, J., Horowitz, M., & Choi, Y. (2008) · Endocrine Reviews · doi:10.1210/er.2007-0038 · Cited by 563
Hymowitz, S. G., Filvaroff, E. H., Yin, J., Lee, J., Cai, L., Risser, P., Maruoka, M., Mao, W., Foster, J., Kelley, R. F., et al. (2001) · The EMBO Journal · doi:10.1093/emboj/20.19.5332 · Cited by 548
Mechanisms of joint destruction in rheumatoid arthritis — immune cell–fibroblast–bone interactions
Komatsu, N., & Takayanagi, H. (2022) · Nature Reviews Rheumatology · doi:10.1038/s41584-022-00793-5 · Cited by 527
Fos/AP‐1 proteins in bone and the immune system
Wagner, E. F., & Eferl, R. (2005) · Immunological Reviews · doi:10.1111/j.0105-2896.2005.00332.x · Cited by 537
An overview of the regulation of bone remodelling at the cellular level
Kular, J., Tickner, J., Chim, S. M., & Xu, J. (2012) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2012.03.021 · Cited by 534
Osteoimmunology: The conceptual framework unifying the immune and skeletal systems
Okamoto, K., Nakashima, T., Shinohara, M., Negishi-Koga, T., Komatsu, N., Terashima, A., Sawa, S., Nitta, T., & Takayanagi, H. (2017) · Physiological Reviews · doi:10.1152/physrev.00036.2016 · Cited by 534
Osteoclasts are essential for TNF-α–mediated joint destruction
Redlich, K., Hayer, S., Ricci, R., David, J.-P., Tohidast-Akrad, M., Kollias, G., Steiner, G., Smolen, J. S., Wagner, E. F., & Schett, G. (2002) · Journal of Clinical Investigation · doi:10.1172/jci15582 · Cited by 531
The Role of IL-17 and related cytokines in inflammatory autoimmune diseases
Kuwabara, T., Ishikawa, F., Kondo, M., & Kakiuchi, T. (2017) · Mediators of Inflammation · doi:10.1155/2017/3908061 · Cited by 519
Kanzaki, H., Chiba, M., Shimizu, Y., & Mitani, H. (2002) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2002.17.2.210 · Cited by 527
“The signal transduction through PGE2 to RANKL has been clarified.((13,29,30)) Cyclic adenosine monophosphate (cAMP) or phosphoinositide 3-kinase can up-regulate RANKL expression, while their specific inhibitors suppress RANKL expression.”
BackgroundLi, Y., Toraldo, G., Li, A., Yang, X., Zhang, H., Qian, W.-P., & Weitzmann, M. N. (2007) · Blood · doi:10.1182/blood-2006-07-037994 · Cited by 520
Sims, N. A., & Gooi, J. H. (2008) · Seminars in Cell & Developmental Biology · doi:10.1016/j.semcdb.2008.07.016 · Cited by 513
Roggia, C., Gao, Y., Cenci, S., Weitzmann, M. N., Toraldo, G., Isaia, G., & Pacifici, R. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.251534698 · Cited by 513
Zhang, Y.-H., Heulsmann, A., Tondravi, M. M., Mukherjee, A., & Abu-Amer, Y. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m008198200 · Cited by 498
Honore, P., Luger, N. M., Sabino, M. A. C., Schwei, M. J., Rogers, S. D., Mach, D. B., O'keefe, P. F., Ramnaraine, M. L., Clohisy, D. R., & Mantyh, P. W. (2000) · Nature Medicine · doi:10.1038/74999 · Cited by 498
Teng, Y.-T. A., Nguyen, H., Gao, X., Kong, Y.-Y., Gorczynski, R. M., Singh, B., Ellen, R. P., & Penninger, J. M. (2000) · Journal of Clinical Investigation · doi:10.1172/jci10763 · Cited by 493
Self-citationOsteoimmunology and the effects of the immune system on bone
Takayanagi, H. (2009) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2009.217 · Cited by 487
Osteoclasts are essential for TNF-α-mediated joint destruction.
Redlich, K., Hayer, S., Ricci, R., David, J.-P., Tohidast-Akrad, M., Kollias, G., Steiner, G., Smolen, J. S., Wagner, E. F., & Schett, G. (2002) · Journal of Clinical Investigation · doi:10.1172/jci0215582 · Cited by 474
Host response mechanisms in periodontal diseases
SILVA, N., ABUSLEME, L., BRAVO, D., DUTZAN, N., GARCIA-SESNICH, J., VERNAL, R., HERNÁNDEZ, M., & GAMONAL, J. (2015) · Journal of Applied Oral Science · doi:10.1590/1678-775720140259 · Cited by 471
Immune Response: The Key to Bone Resorption in Periodontal Disease
Taubman, M. A., Valverde, P., Han, X., & Kawai, T. (2005) · Journal of Periodontology · doi:10.1902/jop.2005.76.11-s.2033 · Cited by 460
Deciphering osteoarthritis genetics across 826,690 individuals from 9 populations
Boer, C. G., Hatzikotoulas, K., Southam, L., Stefánsdóttir, L., Zhang, Y., Coutinho de Almeida, R., Wu, T. T., Zheng, J., Hartley, A., Teder-Laving, M., et al. (2021) · Cell · doi:10.1016/j.cell.2021.07.038 · Cited by 434
“Of the 77 genes with three different lines of evidence supporting causality, 20 are tier 1 candidates (18 of these are present in DrugBank) (Table 4; STAR Methods), 16 Cell 184, 1–35, September 2, 2021 of which 7 correspond to new genetic signals discovered in this study (CHST3, VDR, TNFSF11, IGF1R, NR3C1, CHRM2, and…”
InfluentialSignaling Pathways in Mammary Gland Development
Hennighausen, L., & Robinson, G. W. (2001) · Developmental Cell · doi:10.1016/s1534-5807(01)00064-8 · Cited by 422
Activity loss and the onset of depressive symptoms: Do some activities matter more than others?
Katz, P. P., & Yelin, E. H. (2001) · Arthritis & Rheumatism · doi:10.1002/1529-0131(200105)44:5<1194::aid-anr203>3.0.co;2-6 · Cited by 175
RANK/RANKL: Regulators of Immune Responses and Bone Physiology
Leibbrandt, A., & Penninger, J. M. (2008) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1443.016 · Cited by 420
Self-citationKotake, S., Udagawa, N., Hakoda, M., Mogi, M., Yano, K., Tsuda, E., Takahashi, K., Furuya, T., Ishiyama, S., Kim, K., et al. (2001) · Arthritis & Rheumatism · doi:10.1002/1529-0131(200105)44:5<1003::aid-anr179>3.0.co;2-# · Cited by 420
Cadherin-11 in Synovial Lining Formation and Pathology in Arthritis
Lee, D. M., Kiener, H. P., Agarwal, S. K., Noss, E. H., Watts, G. F. M., Chisaka, O., Takeichi, M., & Brenner, M. B. (2007) · Science · doi:10.1126/science.1137306 · Cited by 420
Mechanistic insight into osteoclast differentiation in osteoimmunology
Takayanagi, H. (2005) · Journal of Molecular Medicine · doi:10.1007/s00109-004-0612-6 · Cited by 413
“Penninger and colleagues [8, 12, 13] contributed to the development of osteoimmunology by generating a series of knockout mice and establishing the role of the RANKL/ RANK system in the pathogenesis of bone diseases and published an extensive review article on the RANKL system [14].”
BackgroundRomas, E., Gillespie, M. T., & Martin, T. J. (2002) · Bone · doi:10.1016/s8756-3282(01)00682-2 · Cited by 411
AGA technical review on osteoporosis in gastrointestinal diseases
Bernstein, C. N., Leslie, W. D., & Leboff, M. S. (2003) · Gastroenterology · doi:10.1053/gast.2003.50106 · Cited by 412
Osteoporosis, inflammation and ageing
Ginaldi, L., Di Benedetto, M. C., & De Martinis, M. (2005) · Immunity & Ageing · doi:10.1186/1742-4933-2-14 · Cited by 412
RANK Ligand and Osteoprotegerin: Paracrine Regulators of Bone Metabolism and Vascular Function
Schoppet, M., Preissner, K. T., & Hofbauer, L. C. (2002) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.0000012303.37971.da · Cited by 405
Eriksson, U., Ricci, R., Hunziker, L., Kurrer, M. O., Oudit, G. Y., Watts, T. H., Sonderegger, I., Bachmaier, K., Kopf, M., & Penninger, J. M. (2003) · Nature Medicine · doi:10.1038/nm960 · Cited by 405
“RANK-RANKL interactions were blocked using a human OPG fusion protein at 250 μg/mous”
MethodSelf-citationMakarov, S. S. (2001) · Arthritis Research · doi:10.1186/ar300 · Cited by 447
Udagawa, N., Takahashi, N., Yasuda, H., Mizuno, A., Itoh, K., Ueno, Y., Shinki, T., Gillespie, M. T., Martin, T. J., Higashio, K., et al. (2000) · Endocrinology · doi:10.1210/en.141.9.3478 · Cited by 404
Lubberts, E., Joosten, L. A. B., Oppers, B., van den Bersselaar, L., Coenen-de Roo, C. J. J., Kolls, J. K., Schwarzenberger, P., van de Loo, F. A. J., & van den Berg, W. B. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.167.2.1004 · Cited by 401
Pike, J. W., & Meyer, M. B. (2010) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2010.02.007 · Cited by 394
TNF ligands and receptors – a matter of life and death
MacEwan, D. J. (2002) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0704549 · Cited by 391
“Likewise RANK and highly related receptors such as OPG control bone formation and integrity resulting in various bone density disorders (Wuyts et al., 2001; Kim et al., 2000; Li et al., 2000; Hughes et al., 2000; Kong et al., 1999).”
BackgroundTreg cells suppress osteoclast formation: A new link between the immune system and bone
Zaiss, M. M., Axmann, R., Zwerina, J., Polzer, K., Gückel, E., Skapenko, A., Schulze‐Koops, H., Horwood, N., Cope, A., & Schett, G. (2007) · Arthritis & Rheumatism · doi:10.1002/art.23138 · Cited by 388
Osteocyte-Related Cytokines Regulate Osteoclast Formation and Bone Resorption
Kitaura, H., Marahleh, A., Ohori, F., Noguchi, T., Shen, W.-R., Qi, J., Nara, Y., Pramusita, A., Kinjo, R., & Mizoguchi, I. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21145169 · Cited by 380
“bone marrow stromal cells [6], and lymphocytes [7].”
BackgroundThe Osteoclast: Friend or Foe?
Novack, D. V., & Teitelbaum, S. L. (2008) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev.pathmechdis.3.121806.151431 · Cited by 381
Rheumatic diseases: the effects of inflammation on bone
Walsh, N. C., Crotti, T. N., Goldring, S. R., & Gravallese, E. M. (2005) · Immunological Reviews · doi:10.1111/j.0105-2896.2005.00338.x · Cited by 380
NF-κB as a therapeutic target in chronic inflammation: recent advances
Makarov, S. S. (2000) · Molecular Medicine Today · doi:10.1016/s1357-4310(00)01814-1 · Cited by 379
The Cellular and Molecular Biology of Periprosthetic Osteolysis
Purdue, P. E., Koulouvaris, P., Potter, H. G., Nestor, B. J., & Sculco, T. P. (2007) · Clinical Orthopaedics and Related Research · doi:10.1097/01.blo.0000238813.95035.1b · Cited by 372
Yu, J. J., Ruddy, M. J., Wong, G. C., Sfintescu, C., Baker, P. J., Smith, J. B., Evans, R. T., & Gaffen, S. L. (2007) · Blood · doi:10.1182/blood-2005-09-010116 · Cited by 372
Osteoprotegerin Reduces Osteoclast Numbers and Prevents Bone Erosion in Collagen-Induced Arthritis
Romas, E., Sims, N. A., Hards, D. K., Lindsay, M., Quinn, J. W. M., Ryan, P. F. J., Dunstan, C. R., Martin, T. J., & Gillespie, M. T. (2002) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)64417-3 · Cited by 368
“When taken together with our results, the findings by Kong et al.20 support the notion that, compared to AIA, cartilage destruction in CIA is less dependent on RANK signaling events such as osteoclastic bone destruction.”
BackgroundResultInfluentialBone loss in inflammatory disorders
Hardy, R., & Cooper, M. S. (2009) · Journal of Endocrinology · doi:10.1677/joe-08-0568 · Cited by 365
Osteocytes as mechanosensors in the inhibition of bone resorption due to mechanical loading
You, L., Temiyasathit, S., Lee, P., Kim, C. H., Tummala, P., Yao, W., Kingery, W., Malone, A. M., Kwon, R. Y., & Jacobs, C. R. (2008) · Bone · doi:10.1016/j.bone.2007.09.047 · Cited by 359
The role of the immune system in the pathophysiology of osteoporosis
Clowes, J. A., Riggs, B. L., & Khosla, S. (2005) · Immunological Reviews · doi:10.1111/j.0105-2896.2005.00334.x · Cited by 359
Noss, E. H., & Brenner, M. B. (2008) · Immunological Reviews · doi:10.1111/j.1600-065x.2008.00648.x · Cited by 357
Metadata
- Authors
- Kong, Y.-Y., Feige, U., Sarosi, I., Bolon, B., Tafuri, A., Morony, S., Capparelli, C., Li, J., Elliott, R., McCabe, S., Wong, T., Campagnuolo, G., Moran, E., Bogoch, E. R., Van, G., Nguyen, L. T., Ohashi, P. S., Lacey, D. L., Fish, E., Boyle, W. J., & Penninger, J. M.
- Affiliations
- Amgen (Canada) (CA)
- Amgen (United States) (US)
- St. Michael's Hospital (CA)
- University of Toronto (CA)
- ORCID
- Venue
- Nature
- Published
- 1999-11
- Volume
- 402
- Issue
- 6759
- Pages
- 304-309
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W1677043489
- Cited by
- 1,856
- References
- 24
- Citations by year
- 2026: 17 · 2025: 33 · 2024: 36 · 2023: 33 · 2022: 25 · 2021: 36 · 2020: 47 · 2019: 43 · 2018: 38 · 2017: 59 · 2016: 64 · 2015: 82 · 2014: 80 · 2013: 85 · 2012: 77
- FWCI
- 26.88
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Funders
- Cystic Fibrosis Foundation
- U.S. Public Health Service
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bone Metabolism and Diseases
- Health Sciences › Medicine › Rheumatology › Rheumatoid Arthritis Research and Therapies
- Health Sciences › Medicine › Rheumatology › Osteomyelitis and Bone Disorders Research
- Keywords
- osteoprotegerin ligand, osteoprotegerin, RANK, activated T cells, adjuvant-induced arthritis, bone loss, osteoclastogenesis, joint destruction, cartilage destruction, T cell activation, bone remodeling, osteoclasts
- MeSH terms
- Animals, Arthritis, Experimental, Bone and Bones, Bone Resorption, Carrier Proteins, Cartilage, Cells, Cultured, Glycoproteins, Humans, Lymphocyte Activation, Membrane Glycoproteins, Mice, Inbred C57BL, Rats, Inbred Lew, T-Lymphocytes, Receptors, Tumor Necrosis Factor, Receptors, Cytoplasmic and Nuclear, Coculture Techniques, Mice, Rats, Osteoprotegerin, RANK Ligand, Receptor Activator of Nuclear Factor-kappa B
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.